(Reuters) – French vaccine developer Valneva targets increasing its revenues year-on-year by up to 70% thanks to a boost from its COVID-19 vaccine candidate, it said on Thursday.
The company sees 2022 revenue of between 430 million to 590 million euros ($485.73 million to $666.46 million), including 350 million to 500 million euros of COVID-19 vaccine sales, which are still subject to regulatory approvals and deliveries of their COVID vaccine candidate called VLA2001.
Valneva’s 2021 revenue soared 216% year-on-year to 348.1 million euros mainly on COVID-related revenues under a terminated agreement in Britain.
($1 = 0.8853 euros)
(Reporting by Piotr Lipinski in Gdansk; Editing by Christian Schmollinger)
